Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb;19(2):9.
doi: 10.1007/s11912-017-0567-8.

Radionuclide Therapy for Neuroendocrine Tumors

Mauro Cives  1 , Jonathan Strosberg  2
Affiliations
Review

Radionuclide Therapy for Neuroendocrine Tumors

Mauro Cives et al. Curr Oncol Rep. 2017 Feb.

Abstract

Peptide receptor radionuclide therapy (PRRT) is a form of systemic radiotherapy that allows targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin receptors. The two radiopeptides most commonly used for PRRT, 90Y-DOTATOC and 177Lu-DOTATATE, have been successfully employed for more than a decade for the treatment of advanced neuroendocrine tumors (NETs). Recently, the phase III, randomized NETTER-1 trial has compared 177Lu-DOTATATE versus high-dose octreotide LAR in patients with progressive, metastatic midgut NETs, demonstrating exceptional tolerability and efficacy. This review summarizes recent developments in the field of radionuclide therapy for gastroenteropancreatic and lung NETs and considers possible strategies to further enhance its clinical efficacy.

Keywords: Carcinoid tumors; Lutetium; NETTER-1; PRRT; Radiolabeled somatostatin analogs.

PubMed Disclaimer

References

    1. J Nucl Med. 2014 Feb;55(2):183-90 - PubMed
    1. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1964-70 - PubMed
    1. J Nucl Med. 2002 May;43(5):610-6 - PubMed
    1. Eur J Surg Oncol. 2012 Jan;38(1):64-71 - PubMed
    1. J Nucl Med. 2005 Jan;46 Suppl 1:83S-91S - PubMed

MeSH terms

LinkOut - more resources